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Microwave Hyperthermia at 2450 and 915 Megahertz Frequenciest
Kenneth H. Luk, MD*

Microwave hyperthermia at frequencies of 2450 and 915
megahertz (MHz) was used to treat superficial measurable
tumors of different histopathologies at various sites. Fortyseven patients received 59 courses of treatment; they were
able to tolerate temperatures up to 42.5X1. Although hyperthermia alone (40°-42.5°C) did not produce an effective
response, hyperthermia and radiation together (up to 2700
rad in nine fractions over three weeks) produced complete

and partial responses in three-fourths of the treatment
courses. The combination of hyperthermia and chemotherapy may have great potential, but confirmation of
these clinical impressions will depend on a much larger
series of patient data. We urge participation in cooperative
studies such as the Hyperthermia Study Group of the
Radiation Therapy Oncology Group.

Encouraged by numerous promising reports of the tumoricidal effects of hyperthermia in vivo and in vitro (1-4),
a clinical hyperthermia program was started at the Claire
Zellerbach Saroni Tumor Institute of Mount Zion Hospital
and Medical Center in December 1976. This paper presents an updated analysis of results of treatment of 47
cancer patients with microwave hyperthermia at frequencies of 2450 and 915 megahertz (MHz) treated between
December 1976 and June 1980.

MHz microwave, which was delivered by a dielectric-filled
applicator measuring 8 x 8 cm. Effective heating can be
achieved in tissues up to 4.5 cm deep.
Thermometry
Temperature measurements of tumor tissues were made by
inserting a Yellow Springs (Model 524) thermistor needle at
the desired depth, with the needle positioned carefully at
right angles tothe electric field to minimize heating perturbance. This needle was left in situ for continuous temperature monitoring, wfth measurements being made at fiveminute intervals. Periodically, skin temperature was also
monitored. Skin cooling was not used for the patients
described in this report but was adopted for patients treated
later.

Materials and Methods
Instrumentation
A diathermy unit (Burdick Corp, Model MW/200) generated 2450 MHz microwave which was broadcast by Burdick Type B or E applicators (either an 8 cm diameter circle
or 14 X 17 cm rectangle). Since heat induction will reach
tissues no deeper than about one centimeter, only superficial lesions can be treated with this equipment.

The prescribed tumor temperature of 42.5°C could not
always be achieved, due to many factors, including heat
conduction by local vasculature and patient intolerance.
Treatment schedule

A variable frequency (400 MHz-1000 MHz) MCL (Model
15122) radiofrequency generator was used to produce 915

Most patients were treated three times a week on Mondays,
Wednesdays, and Fridays for two or three weeks, for a total
of six or nine treatments of hyperthermia. Some patients
were treated twice a week on a Monday-Thursday, or
Tuesday-Friday schedule, which was devised because of
the in vitro observation of the phenomenon of "thermotolerance" (5,6).
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For patients who received combined hyperthermia and
radiation, the hyperthermia was given immediately after
radiation; it was usually delivered as an electron beam of
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the appropriate energy for the depth of the tumor at 300 rad
per fraction. For the few patients on the combined chemotherapy and hyperthermia protocol, chemotherapeutic
drugs were given (bleomycin intravenously in 5 mg bolus
for head and neck cancers) one to two hours before local
hyperthermia. A low dosage was purposely chosen so that
it would not mask or strongly affect any efficacy of the
hyperthermia treatment.

only parameter that could be evaluated. Treatment responses were rated as complete (CR=100% regression),
partial (PR>50% regression), and no response (NR<50%
regression).

Results
Fifty-seven patients received hyperthermia, but ten patients
could not be evaluated because of early deaths, inadequate
measurable lesions, premature surgical excision, or because they were lost to follow-up. The distribution of the
different types of tumors treated by hyperthermia (Table I)
was not representative of the cases treated with radiation
therapy in our department. Most of the patients treated with
2450 MHz microwave had chest wall recurrence of breast
cancer after mastectomy, radiotherapy and chemotherapy,
or hormonal therapy. On the other hand, many patients
treated with 915 MHz microwave had nodal recurrences in
previously irradiated areas in the neck or groin. Some
patients were treated with hyperthermia in more than one
site. A few sites received two series of treatments with a
time interval between them. Altogether, 40 courses were
given with 2450 MHz and 19 courses with 915 MHz
microwave.

Patient population
The patients were enrolled in one of four programs:
1) hyperthermia only, 2) hyperthermia and radiotherapy,
3) hyperthermia and chemotherapy, and 4) hyperthermia
plus radiotherapy and chemotherapy. To date, most patients received either hyperthermia alone or hyperthermia
and radiotherapy.
Patients accepted for this hyperthermia treatment program
had observable, measurable, recurrent or metastatic tumors
and had failed conventional cancer treatments. Ionizing
radiation was added to hyperthermia when previous radiotherapy did not exceed normal tissue tolerance, usually
as a dose equivalence of about 6000 rad in six weeks.
Method of evaluation

Hyperthermia alone vs hyperthermia and radiation
(Table II)

Measurements were made before, during, and after a treatment course, and at frequent follow-up examinations. The
size of a treated lesion was measured with a caliper in at
least two dimensions, and the depth of a tumor was measured whenever possible. Polaroid color photographs were
taken to ensure documentation, and notes were detailed to
describe observations of tumor regression, normal tissue
effects, and patient's status.

At the 40°-42.5°C range, hyperthermia alone did not seem
to be effective in inducing tumor regression. However,
when hyperthermia was given after low dose radiation
(mostly 1800 rad/six fractions to 2700 rad/nine fractions), a
higher response rate was observed. Since most of these
patients died within a few months after treatment, a study
of the duration of responses would not be meaningful.

Since this group of patients had advanced cancers, survival
after treatment was short. Local tumor response became the

Renal cell carcinoma and sarcoma seemed to have a lower
rate of t u m o r response. The one case of melanoma

TABLE I
Histopathology of Lesions Treated by Microwave Hyperthermia
915 MHz

2450 MHz
No. of
patients
27
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No. of
patients

Histopathology

Histopathology

Breast carcinoma

2

Renal carcinoma

Breast sarcoma

3

Nasopharyngeal carcinoma

Chondrosarcoma

2

Colonic carcinoma

1

Histiocytic lymphoma

1

Rectal carcinoma

1

Rectal carcinoma

2

Breast carcinoma

1

Vaginal carcinoma

Total = 31

1

Floor-of-mouth carcinoma

2

Laryngeal carcinoma

1

Melanoma

1

Lung

Total = 16
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achieved nearly complete regression after hyperthermia
and radiation, but there was residual induration on clinical
palpation.

Discussion
To date, we have found that microwave hyperthermia
delivered in the manner described has been generally well
tolerated. Unfortunately, hyperthermia alone to a temperature of 42.5°C has not been successful in producing tumor
regression. Higher temperatures may be more effective, but
they may also be associated with greater morbidity.

TABLE II
Local Tumor Response to Hyperthermia Alone
and Hyperthermia and Radiation
Primary Site

Hyperthermia
alone
CR PR NR

However, hyperthermia (42.5°C) combined with low-dose
radiation has produced significant tumor responses. Since
most of our patients had received previous radiotherapy,
we kept the dose of radiation low out of consideration for
their safety. It may be possible to achieve improved local
control of bulky tumors by combining hyperthermia with
moderate doses of radiation. This concept is appealing to
radiation oncologists since local control of bulky, hypoxic
tumors remains a real challenge.

Hyperthermia
Radiation
CR PR NR

Adenocarcinoma
Breast

10

Rectum

13
1

Colon
Ovary
Kidney

Similarly, the possibility of improved local control with
hyperthermia and chemotherapy is exciting. Dramatic results have been reported in vivo and in vitro (7-9), but our
experience in this regard has been anecdotal. A larger
series of patients will be required in order to draw any
conclusions.

Squamous cell carcinoma
Head and Neck
Lung
Vagina
Sarcoma
Extremity

Clinical applications of our present treatment system have
marked limitations. The problems of accomplishing satisfactory thermal dosimetry in conformance with clinical
requirements have been addressed (10). Also, we need to
carry out more research and development on equipment
that will produce better heat delivery and thermometry.
Certainly, there is plenty of room for innovative designs and
treatment techniques that approach different anatomical
locations of cancerous tumors.

Breast
Melanoma
Extremity
Lymphoma
Lymphatics
Total

15

18

11

CR = complete response; PR = partial response; NR = no response

With our present knowledge of hyperthermia, the importance of sharing information and of cooperative studies
cannot be stressed enough. Much human and material
resources can be saved by a well-planned, concerted scientific effort. Participation in the Hyperthermia Study
Group of the Radiation Therapy Oncology Group (RTOG)
is therefore worthwhile.

Hyperthermia and chemotherapy
We studied only four cases of combined treatments of
hyperthermia and chemotherapy. All were squamous cell
carcinoma recurrent in the neck from nasopharyngeal and
laryngeal primary tumors. As mentioned previously, the
chemotherapy consisted of bleomycin (5 mg intravenously)
one to two hours before hyperthermia. Three of the four
patients also received 2700 rad in nine fractions with
electron beam. One patient who received hyperthermia
and bleomycin responded completely for two months but
failed at the edge of the treatment area. Two patients who
received hyperthermia, bleomycin, and radiation probably
had complete control of disease; one died accidentally 12
months after treatment, and one continued to be in remission, also at 12 months. The fourth patient had a partial
response, but, at the time of this report, treatment had
ended for only three months.
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